Citation Impact
Citing Papers
Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications
2010
Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): [RETIRED]
2006
Omalizumab for asthma in adults and children
2014
Conflict of Interest in Medical Research, Education, and Practice
2009 Standout
El mercado cautivo de ascensores: una reflexión en torno a la sentencia del Tribunal Supremo de fecha 28 de abril de 1999
2000
RIM1α and Interacting Proteins Involved in Presynaptic Plasticity Mediate Prepulse Inhibition and Additional Behaviors Linked to Schizophrenia
2010 StandoutNobel
Non-motor symptoms of Parkinson's disease: diagnosis and management
2006 Standout
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Parkinson disease
2017 Standout
Evidence‐based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004
2005
Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system - too little activation is bad, too much is even worse
2007
Parkinson's disease
2021 Standout
Rivastigmine for Alzheimer’s disease
2005
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
2005 Standout
Why Olanzapine Beats Risperidone, Risperidone Beats Quetiapine, and Quetiapine Beats Olanzapine: An Exploratory Analysis of Head-to-Head Comparison Studies of Second-Generation Antipsychotics
2006
Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment
2009 Standout
Les fluctuations non motrices de la maladie de Parkinson
2007
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia
2008
Subthalamic nucleus deep brain stimulation: Summary and meta-analysis of outcomes
2006 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance
2012
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
2008
Remission in Schizophrenia: Proposed Criteria and Rationale for Consensus
2005 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Long-term treatment of schizophrenia
2006
Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study
2008
Asthma
2017 Standout
Canadian guideline for Parkinson disease
2019 Standout
Allergic Rhinitis and Its Impact on Asthma
2001 Standout
Parkinson's disease
2015 Standout
Therapeutics of Alzheimer's disease: Past, present and future
2013
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
2014 Standout
Evidence‐Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
Adenotonsillectomy Outcomes in Treatment of Obstructive Sleep Apnea in Children
2010
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
2012
Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines
2012 Standout
mRNA transcript therapy
2014 StandoutNobel
Global strategy for asthma management and prevention: GINA executive summary
2007 Standout
Acetylcholinesterase Inhibitors: Pharmacology and Toxicology
2013 Standout
Subarachnoid haemorrhage
2007 Standout
Levodopa/carbidopa/entacapone in Parkinson’s disease
2009
Systematic review of levodopa dose equivalency reporting in Parkinson's disease
2010 Standout
The new and evolving pharmacotherapy of schizophrenia
2003
An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia
2004
IN VITRO EFFECTS OF ANTIPSYCHOTICS ON HUMAN PLATELET ADHESION AND AGGREGATION AND PLASMA COAGULATION
2007 StandoutNobel
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
2013 Standout
A Meta-analysis of the Efficacy of Second-Generation Antipsychotics
2003
NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease
2013 Standout
How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease?
2004
Calcium antagonists for aneurysmal subarachnoid haemorrhage
2005
Industry sponsorship and research outcome
2012 Standout
Pharmacotherapies for Alzheimer's disease: Beyond cholinesterase inhibitors
2011
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Comprehensive Review on Alzheimer’s Disease: Causes and Treatment
2020 Standout
Chemical Constituents and Pharmacological Activities of Garlic (Allium sativum L.): A Review
2020 Standout
Changes in case fatality of aneurysmal subarachnoid haemorrhage over time, according to age, sex, and region: a meta-analysis
2009 Standout
Magnesium in Man: Implications for Health and Disease
2014 Standout
Pharmacological Treatment of Parkinson Disease
2014
Pharmacological interventions for somatoform disorders in adults
2014 Standout
Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore
2010 Standout
Dissemination and publication of research findings: an updated review of related biases
2010 Standout
Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
2012 Standout
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia
2005
Risperidone versus other atypical antipsychotics for schizophrenia
2011
Progress update: Pharmacological treatment of Alzheimer's disease.
2007
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease
2008
Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease
2007
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
2011 Standout
Therapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
2020 Standout
Calcium antagonists for aneurysmal subarachnoid haemorrhage
2007
Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage
2012 Standout
The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
2018 Standout
Family history of subarachnoid haemorrhage: supplemental value of scrutinizing all relatives.
1997 Standout
Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment
2006
Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children
2012
Predictive Factors of Clinical Response to Cholinesterase Inhibitors in Mild and Moderate Alzheimer's Disease and Mixed Dementia: A One-Year Naturalistic Study
2015
Rivastigmine for Alzheimer's disease
2015
Industry sponsorship and research outcome
2017 Standout
Understanding antipsychotic “atypicality”: a clinical and pharmacological moving target
2003
Cholinesterase inhibitors for Alzheimer's disease
2006 Standout
Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
2012 Standout
Works of I. Bourdeix being referenced
Insights into severe asthma control as assessed by guidelines, pulmonologist, patient, and partner
2010
Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD
2005
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment
2005
Efficacy and Tolerability of Entacapone as Adjunctive Therapy to Levodopa in Patients with Parkinson’s Disease and End-of-Dose Deterioration in Daily Medical Practice: An Open, Multicenter Study
2001
Étude Précoce : évaluation d’un autoquestionnaire de dépistage et prise en charge précoces des fluctuations dans la maladie de Parkinson
2008
A Double-Blind Comparative Study of Clozapine and Risperidone in the Management of Severe Chronic Schizophrenia
2001
Is There a Difference between Levodopa/ Dopa-Decarboxylase Inhibitor and Entacapone and Levodopa/Dopa-Decarboxylase Inhibitor Dose Fractionation Strategies in Parkinson’s Disease Patients Experiencing Symptom Re-Emergence due to Wearing-Off?
2008
Omalizumab-induced decrease of FcɛRI expression in patients with severe allergic asthma
2010
SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction
2012
Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil®AerolizerTM) with salbutamol (VentodiskTM)
2001
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: Interest of the Deco questionnaire
2011
Nicardipine in the prevention of spasm-induced neurological deficits after subarachnoid hemorrhage: A dose-ranging study
1992
Parkinson's disease dementia can be easily detected in routine clinical practice
2010
P1-331 Reduced psychotropic drug use in Alzheimer patients receiving rivastigmine
2004
Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study
2003